Systemic inflammation remodels HDL and impairs reverse cholesterol transport.

Systemic inflammation, whether triggered by acute infection or chronic conditions, fundamentally transforms high-density lipoprotein (HDL) from a protective agent into a dysfunctional particle. This process, often referred to as the "acute-phase response," involves structural remodeling that alters both the quantity and the quality of HDL.

Clinical and effectiveness evidence

Inflammatory states are consistently associated with quantitative reductions in standard lipid markers.

• HDL-C and HDL-P Reduction: During acute inflammation, such as sepsis or severe infection, HDL cholesterol (HDL-C) levels can drop by 50% or more within 24 to 48 hours. NMR spectroscopy has shown that medium-sized HDL particle (HDL-P) concentrations can decrease by up to 58% during endotoxemia.
• Disease Associations: Chronic inflammatory conditions like rheumatoid arthritis and systemic metabolic inflammation replicate these patterns, leading to persistently low HDL-C and reduced particle counts that correlate with increased cardiovascular risk.

Mechanistic explanations

The transition from "healthy" to "inflammatory" HDL is driven by specific proteomic and enzymatic shifts:

• Protein Displacement: The primary structural protein of HDL, apolipoprotein A-I (ApoA-I), is displaced by the acute-phase protein serum amyloid A (SAA). SAA-enriched HDL has a higher affinity for the vascular wall, potentially promoting lipid deposition rather than removal.
• Enzymatic Degradation: Inflammation upregulates endothelial lipase and secretory phospholipase A2 (sPLA2), which hydrolyze HDL phospholipids. This reduces particle size and stability, accelerating the clearance (catabolism) of HDL from the bloodstream.
• Oxidative Modification: Myeloperoxidase (MPO), an enzyme elevated during inflammation, oxidizes specific amino acid residues (such as Tyr192) on ApoA-I. This modification directly impairs the ability of HDL to interact with the ABCA1 transporter, the primary "gatekeeper" for removing cholesterol from macrophages.

Impact on reverse cholesterol transport (RCT)

The functional hallmark of inflammatory HDL is a significant decrease in cholesterol efflux capacity (CEC)—the ability to pull cholesterol out of arterial plaques.

• Efflux Impairment: Studies using macrophage efflux assays demonstrate that inflammatory HDL is 20–40% less effective at accepting cholesterol. This is primarily due to the loss of functional ApoA-I and the inhibitory presence of SAA.
• Pathological Consequences: When RCT is stalled, HDL cannot effectively clear lipids from the arterial wall, leading to increased foam cell formation and plaque instability, regardless of the patient's absolute HDL-C levels.

Bottom line

Systemic inflammation remodels HDL by replacing protective proteins with inflammatory ones, leading to lower HDL-C levels and a significant loss of cholesterol-clearing ability. This "dysfunctional HDL" fails to perform reverse cholesterol transport effectively, increasing cardiovascular vulnerability during inflammatory states.